Home > Resources > Whitepapers > Enhance Precision Oncology Trial Success

Enhance Precision Oncology Trial Success

June 4, 2018

A convergence of biological data and computing power is yielding amazing technological progress in clinical research and development. Vast amounts of data, often from disparate sources, are enabling the transformation of treatment paradigms. In many therapeutic areas, with oncology chief among them, traditional broad-spectrum therapies that produce variable or unsatisfactory outcomes in large populations are being supplanted by precision medicines that produce improved patient outcomes in targeted populations.

Spotlight

Arwan Pharmaceutical Industries, Lebanon

Arwan Pharmaceutical Industries,are one of the most advanced biotech manufacturing facilities in the MENA and Africa. Our ultimate goal is to secure quality critical care medicine to all patients who need them. Thus, quality is embedded in each and every step of our operations, from the buildings, machineries, materials, methods and manpower. Empowered by our passion for achievement, strong belief in our capabilities, and the emphasis on performance with integrity, we continue to work according to our motto:

OTHER WHITEPAPERS

HFPP Fraud, Waste, and Abuse in the Context of COVID-19

whitePaper | January 24, 2022

Since early 2020, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome.

Harnessing the power of the human microbiome

whitePaper | January 20, 2023

We provide an overview of the human microbiome market, the observed challenges, how to overcome them and introduce future opportunities for pharmaceutical.

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

whitePaper | March 22, 2023

If scaling issues strike you as obvious or even boring, you should read “On Being the Right Size,” a 1926 essay by geneticist J.B.S. Haldane. It makes the case that a difference in scale—a seemingly simple matter—may demand subtle changes in form and function.

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.

Effective solutions for global challenges

whitePaper | April 24, 2023

Despite challenging global conditions, the Swiss biotech industry was able to raise more than CHF 1.33 billion in 2022, with roughly CHF 0.78 billion collected by public companies and the remaining CHF 0.55 billion collected by private companies.

State of the Global Biotech Landscape

whitePaper | November 22, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period encompasses a unique timeframe including the global COVID-19 pandemic.